Trials / Completed
CompletedNCT02048059
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Angiochem Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANG1005 |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2016-03-01
- Completion
- 2017-09-01
- First posted
- 2014-01-29
- Last updated
- 2020-02-25
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02048059. Inclusion in this directory is not an endorsement.